Skip to search formSkip to main contentSkip to account menu

DCC-2701

National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

AltiratinibAminopyridinesAnilides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
The type II switch control kinase inhibitor, DCC-2701 (altiratinib) effectively inhibits resistant NTRK kinase domain mutants
2014
2014
AI-25THE NOVEL c-MET INHIBITOR ALTIRATINIB (DCC-2701) INHIBITS TUMOR GROWTH AND INVASION IN A BEVACIZUMAB RESISTANT GLIOBLASTOMA MOUSE MODEL
Glioblastoma with acquired resistance to bevacizumab therapy overexpresses c-MET which mediates tumor growth, EMT, invasion, and… 
2014
2014
355 Altiratinib (DCC-2701): a balanced inhibitor of MET, TIE2, and VEGFR2 kinases that exhibits broad anti-tumor and anti-angiogenic activities
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)